These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 12490654)
1. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Guillermet J; Saint-Laurent N; Rochaix P; Cuvillier O; Levade T; Schally AV; Pradayrol L; Buscail L; Susini C; Bousquet C Proc Natl Acad Sci U S A; 2003 Jan; 100(1):155-60. PubMed ID: 12490654 [TBL] [Abstract][Full Text] [Related]
2. Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells. Rauly I; Saint-Laurent N; Delesque N; Buscail L; Estéve JP; Vaysse N; Susini C J Clin Invest; 1996 Apr; 97(8):1874-83. PubMed ID: 8621771 [TBL] [Abstract][Full Text] [Related]
3. Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways. Guillermet-Guibert J; Saint-Laurent N; Davenne L; Rochaix P; Cuvillier O; Culler MD; Pradayrol L; Buscail L; Susini C; Bousquet C Cell Death Differ; 2007 Feb; 14(2):197-208. PubMed ID: 16645635 [TBL] [Abstract][Full Text] [Related]
4. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Mitsiades N; Poulaki V; Mitsiades C; Tsokos M Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Benali N; Cordelier P; Calise D; Pages P; Rochaix P; Nagy A; Esteve JP; Pour PM; Schally AV; Vaysse N; Susini C; Buscail L Proc Natl Acad Sci U S A; 2000 Aug; 97(16):9180-5. PubMed ID: 10900262 [TBL] [Abstract][Full Text] [Related]
6. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619 [TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Shigeno M; Nakao K; Ichikawa T; Suzuki K; Kawakami A; Abiru S; Miyazoe S; Nakagawa Y; Ishikawa H; Hamasaki K; Nakata K; Ishii N; Eguchi K Oncogene; 2003 Mar; 22(11):1653-62. PubMed ID: 12642868 [TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Zhang XD; Zhang XY; Gray CP; Nguyen T; Hersey P Cancer Res; 2001 Oct; 61(19):7339-48. PubMed ID: 11585775 [TBL] [Abstract][Full Text] [Related]
9. Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Rochaix P; Delesque N; Estève JP; Saint-Laurent N; Voight JJ; Vaysse N; Susini C; Buscail L Hum Gene Ther; 1999 Apr; 10(6):995-1008. PubMed ID: 10223733 [TBL] [Abstract][Full Text] [Related]
10. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Suliman A; Lam A; Datta R; Srivastava RK Oncogene; 2001 Apr; 20(17):2122-33. PubMed ID: 11360196 [TBL] [Abstract][Full Text] [Related]
11. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649 [TBL] [Abstract][Full Text] [Related]
12. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837 [TBL] [Abstract][Full Text] [Related]
13. sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Delesque N; Buscail L; Estève JP; Saint-Laurent N; Müller C; Weckbecker G; Bruns C; Vaysse N; Susini C Cancer Res; 1997 Mar; 57(5):956-62. PubMed ID: 9041201 [TBL] [Abstract][Full Text] [Related]
14. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Ravi R; Bedi A Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014 [TBL] [Abstract][Full Text] [Related]
15. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Ng CP; Zisman A; Bonavida B Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140 [TBL] [Abstract][Full Text] [Related]
17. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Jeremias I; Herr I; Boehler T; Debatin KM Eur J Immunol; 1998 Jan; 28(1):143-52. PubMed ID: 9485194 [TBL] [Abstract][Full Text] [Related]
18. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis. Kim JH; Ajaz M; Lokshin A; Lee YJ Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965 [TBL] [Abstract][Full Text] [Related]
19. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Izeradjene K; Douglas L; Delaney A; Houghton JA Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455 [TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Siegmund D; Hadwiger P; Pfizenmaier K; Vornlocher HP; Wajant H Mol Med; 2002 Nov; 8(11):725-32. PubMed ID: 12520089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]